Toru Mukohara,Yeon Hee Park,David Sommerhalder,Kan Yonemori,Erika Hamilton,Sung-Bae Kim,Jee Hyun Kim,Hiroji Iwata,Toshinari Yamashita,Rachel M. Layman,Monica Mita,Timothy Clay,Yee Soo Chae,Catherine Oakman,Fengting Yan,Gun Min Kim,Seock-Ah Im,Geoffrey J. Lindeman,Hope S. Rugo,Marlon Liyanage,Michelle Saul,Christophe Le Corre,Athanasia Skoura,Li Liu,Meng Li,Patricia M. LoRusso

Abstract:Inhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER + ) breast cancer preclinical models. PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B. In the present study, we report the safety, pharmacokinetics (PK), pharmacodynamics, efficacy and biomarker results from the first-in-human, phase 1 dose escalation and dose expansion study ( n = 107) of PF-07248144 monotherapy and fulvestrant combination in heavily pretreated ER + human epidermal growth factor receptor-negative (HER2 − ) metastatic breast cancer (mBC). The primary objectives of assessing the safety and tolerability and determining the recommended dose for expansion of PF-07248144, as monotherapy and in combination with fulvestrant, were met. Secondary endpoints included characterization of PK and evaluation of antitumor activity, including objective response rate (ORR) and progression-free survival (PFS). Common treatment-related adverse events (any grade; grades 3–4) included dysgeusia (83.2%, 0%), neutropenia (59.8%, 35.5%) and anemia (48.6%, 13.1%). Exposure was approximately dose proportional. Antitumor activity was observed as monotherapy. For the PF-07248144–fulvestrant combination ( n = 43), the ORR (95% confidence interval (CI)) was 30.2% (95% CI = 17.2–46.1%) and the median PFS was 10.7 (5.3–not evaluable) months. PF-07248144 demonstrated a tolerable safety profile and durable antitumor activity in heavily pretreated ER + HER2 − mBC. These findings establish KAT6A and KAT6B as druggable cancer targets, provide clinical proof of concept and reveal a potential avenue to treat mBC. clinicaltrial.gov registration: NCT04606446.

Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER + HER2 − metastatic breast cancer: a phase 1 trial

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Inhibition of lysine acetyltransferase KAT6 in ER + HER2 − metastatic breast cancer: a phase 1 trial

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Corrigendum to 'inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer' [ebiomedicine 31 (2018) 276-286].

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Erratum: Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Correction: Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer

Author Correction: The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer

Author Correction: An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation

Correction: Corrigendum: Selective Killing of Cancer Cells by a Small Molecule Targeting the Stress Response to ROS

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

Correction: Corrigendum: A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation

Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity